Dose-enhancement of MCF 7 cell line radiotherapy using silica-iron oxide nanocomposite

Biochem Biophys Res Commun. 2022 Dec 3:632:100-106. doi: 10.1016/j.bbrc.2022.09.087. Epub 2022 Sep 27.

Abstract

Cancer radiotherapy is one of the most effective regimens of cancer treatments, but cancer cell radioresistance remains a concern. Radiosensitizers can selectively improve the efficacy of radiotherapy and reduce inherent damage. The purpose of this work is to evaluate the effect of silica-coated iron oxide magnetic nanoparticles (SIONPs) as a radiosensitizer and compare their therapeutic effect with that of Iron oxide magnetic nanoparticles (IONPs). IONPs and SIONPs were characterized using several physical techniques such as a transmission electron microscope (TEM) and Vibrating sample magnetometer (VSM). MTT and DNA double-strand breaks (Comet) assays have been used to detect the cytotoxicity, cell viability, and DNA damage of MCF-7 cells, which were treated with different concentrations of prepared nanoparticles and exposed to an X-ray beam. In this study, an efficient radiosensitizer, SIONPs, was successfully prepared and characterized. With 0.5 Gy dose, dose enhancement factor (DEF) values of cells treated with 5 and 10 μg/ml of IONPs were 1 and 1.09, respectively, while those treated with SIONPs at these concentrations had DEF of 1.21 and 1.32, respectively. Results demonstrated that SIONPs provide a potential for improving the radiosensitivity of breast cancer.

Keywords: Breast cancer; Cytotoxicity; Iron oxide magnetic nanoparticles (IONPs); Nano-radiosensitizer; Radiation therapy.

MeSH terms

  • Cell Survival
  • DNA
  • Humans
  • MCF-7 Cells
  • Nanocomposites*
  • Radiation-Sensitizing Agents* / pharmacology
  • Silicon Dioxide

Substances

  • DNA
  • ferric oxide
  • Radiation-Sensitizing Agents
  • Silicon Dioxide